Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

16.6K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.6K
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
Small interfering RNAs (siRNA)02:30

Small interfering RNAs (siRNA)

3.5K
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Droplet Digital PCR Measurement of HBV DNA in On-Treatment Chronic HBV Patients: Association With HCC Development and Outcomes.

Journal of viral hepatitis·2026
Same author

Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis.

Liver cancer·2026
Same author

Mass hepatitis C virus screening among persons in custody in Hong Kong: a modelling cost-effectiveness analysis based on a prospective cohort study.

The Lancet regional health. Western Pacific·2026
Same author

Review Article: Renal Safety Profiles of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, and Entecavir for the Treatment of Chronic Hepatitis B Infection-General and Special Populations.

Alimentary pharmacology & therapeutics·2026
Same author

Impact of SGLT2i and GLP-1RA on liver-related events in patients with MASLD and type 2 diabetes: A network meta-analysis.

JHEP reports : innovation in hepatology·2026
Same author

The magic of sodium-glucose cotransporter-2 inhibitors (SGLT2-i) - Benefits in metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2D).

Clinical and molecular hepatology·2026

Related Experiment Video

Updated: Jun 5, 2025

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

7.8K

Investigational RNA Interference Agents for Hepatitis B.

Rex Wan-Hin Hui1, Lung-Yi Mak1,2, Wai-Kay Seto1,2

  • 1Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam Road, Pok Fu Lam, Hong Kong.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|December 7, 2024
PubMed
Summary

RNA interference (RNAi) therapies show promise for a functional cure of chronic hepatitis B (CHB). These novel treatments effectively suppress hepatitis B surface antigen (HBsAg) and may lead to immune recovery.

More Related Videos

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
05:55

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

6.7K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.2K

Related Experiment Videos

Last Updated: Jun 5, 2025

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

7.8K
Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
05:55

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

6.7K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.2K

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Functional cure for chronic hepatitis B (CHB) remains challenging with current treatments.
  • Achieving sustained HBsAg seroclearance is an optimal, yet difficult, treatment goal.

Purpose of the Study:

  • To evaluate RNA interference (RNAi) as a novel therapeutic strategy for CHB.
  • To assess the efficacy of RNAi in suppressing HBV replication and promoting immune reconstitution.

Main Methods:

  • RNA interference (RNAi) utilizes small-interfering RNA (siRNA) or antisense oligonucleotides (ASO) to target HBV post-transcriptional RNA.
  • Investigated RNAi therapeutics in phase II/III clinical trials for their effects on HBsAg suppression and seroclearance.

Main Results:

  • RNAi therapeutics demonstrated potent, dose-dependent, and sustainable suppression of HBsAg.
  • HBsAg seroclearance was observed, particularly with antisense oligonucleotide (ASO) therapies.
  • Combination therapies (RNAi with antivirals/immunomodulators) showed enhanced efficacy and durability.

Conclusions:

  • RNAi therapeutics represent a promising new modality for CHB treatment.
  • Further research is needed to optimize protocols, identify response predictors, and confirm long-term outcomes.
  • RNAi is poised to become a cornerstone of future hepatitis B treatment strategies.